Regeneron to expand development deal with Intellia Therapeutics

Shares of Regeneron Pharmaceuticals Inc. REGN, -1.05% were down 0.5% in premarket trading on Monday after the company said it had expanded a collaboration with Intellia Therapeutics Inc. NTLA, +14.67% to include CRISPR/Cas9-based therapeutic targets and a new focus on developing treatments for hemophilia A and B.